Saturday, July 11, 2026
🇺🇸 FDA

Drug profile · INN

standard

standard is an FDA-listed pharmaceutical active ingredient.

NMPA: clinical trials
Patents linked 8
Pipeline programs 92
News articles 0
Drug details — standard
Class
—
Route
—
Patents
8
Programs
92
Data quality
0.70
← All drugs Related patents Pipeline programs Drug news hub Event calendar

Quick answer

standard is an FDA-listed pharmaceutical active ingredient.

Key facts

INN standard

Approval history

Authority Status Date
NMPA clinical trials —

Pipeline programs

Browse pipeline
  1. 2023/3720 UMBRELLA Phase 3 · George Institute for · patients with a positive status for molecular residual disea
  2. 217102 Phase 3 · GSK Glaxo Smith · Relapsing or refractory Eosinophilic Granulomatosis with Pol
  3. APHP200026 Phase 3 · PARItec · Patients with GPA and inadequate response to standard of car
  4. Candesartan and standard chronic heart disease therapy Phase 3 · Takeda · Heart Failure
  5. DAPA-PedHKD Phase 3 · Chinese Academy of · Pediatric Hereditary Kidney Diseases
  6. DIDaC/ NVALT35 Phase 3 · Disc Medicine · Patients with advanced, metastatic NSCLC that have not progr
  7. Direct-Acting Oral Anticoagulants (used as per local standard practice) Phase 3 · United Therapeutics Europe · Traumatic Intracranial Haemorrhage
  8. Drug Isotretinoin (13 cis retinoic acid ) capsules+standard treatment Phase 3 · United Therapeutics Europe · COVID19

Related patents

Browse patents

  1. US 11077241

    Standardizations and medical devices for the preparation of platelet rich plasma (PRP) or bone marrow concentrate (BMC) alone or in combination with hyaluronic acid

    Expires Mon Jul 29 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 8487097

    Reference standard for characterization of rosuvastatin

    Expires Mon Jul 11 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 7741482

    Reference standard for characterization of rosuvastatin

    Expires Mon Jun 17 2030 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 7692010

    Reference standard for characterization of rosuvastatin

    Expires Mon Apr 01 2030 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 7692009

    Reference standard for characterization of rosuvastatin

    Expires Mon Apr 01 2030 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 7692008

    Reference standard for characterization of rosuvastatin

    Expires Mon Apr 01 2030 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 7378553

    Isolated atomoxetine impurity, processes for the preparation of atomoxetine impurities and their use as reference standards

    Expires Mon May 22 2028 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 7244844

    Reference standard for characterization of rosuvastatin

    Expires Mon Jul 12 2027 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

What is standard?

standard is an FDA-listed pharmaceutical active ingredient.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.